Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity
Sign Up to like & getrecommendations! Published in 2018 at "Neurological Sciences"
DOI: 10.1007/s10072-018-3487-y
Abstract: No evidence of disease activity-3 (NEDA-3), defined as absence of clinical relapse, disability progression, and brain magnetic resonance imaging (MRI) activity, has emerged as the therapeutic target of disease-modifying therapy for multiple sclerosis (MS). However,… read more here.
Keywords: evidence disease; disease; disease activity; multiple sclerosis ... See more keywords
Brain volume loss and no evidence of disease activity over 3 years in multiple sclerosis patients under interferon beta 1a subcutaneous treatment
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Neuroscience"
DOI: 10.1016/j.jocn.2018.10.095
Abstract: The objective of our study was to evaluate the relationship of percentage of annualized brain volume loss (aBVL) and no evidence of disease activity (NEDA) in multiple sclerosis (MS) patients under interferon beta 1-a subcutaneous… read more here.
Keywords: evidence disease; disease; disease activity; brain volume ... See more keywords
What Proportion of Patients With Musculoskeletal Sarcomas Demostrate Symptoms of Depression or Anxiety?
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Orthopaedics and Related Research"
DOI: 10.1097/corr.0000000000002295
Abstract: Abstract Background It is estimated that the 12-month prevalence of depression in the United States is 8.6%, and for anxiety it is 2.9%. Although prior studies have evaluated depression and anxiety in patients with carcinoma,… read more here.
Keywords: proportion; evidence disease; disease; depression ... See more keywords
Effectiveness of Natalizumab in Achieving No Evidence of Disease Activity (NEDA-3)—Data From a Local Norwegian Cohort
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Neurology"
DOI: 10.3389/fneur.2021.765837
Abstract: Objective: We aimed to determine the effectiveness of natalizumab (NTZ) by assessing overall No Evidence of Disease Activity 3 (NEDA-3) in a local Norwegian cohort. Background: NTZ is an immunomodulating drug used in the treatment… read more here.
Keywords: treatment; evidence disease; disease; cohort ... See more keywords